AI and machine learning drug development firm BenevolentAI has highlighted further data supporting its hypothesis that Eli Lilly’s Olumiant (baricitinib) could be
The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with
